Sign up Australia
Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals’ medicinal cannabis plants enter flowering phase

The harvesting of the plants will commence in the next 2 weeks.
cannabis cultivation
The biomass will be processed into cannabidiol crystals

MGC Pharmaceuticals Ltd’s (ASX:MXC) Czech Republic operation is progressing well with over 450 medicinal cannabis plants entering the flowering phase.

The growth and yield from the plants have been better than expected (for a first time crop) in the new 1,100 square metre glass house facility.

Importantly, the harvesting of the plants will commence in the next 2 weeks.

Once harvested, biomass will be processed into CBD (cannabidiol) crystals for MGC’s products including the MGC Derma cosmetics and for the company’s clinical studies.

The remaining biomass will be sold as Aquiol, a rich >98% CBD purity raw material.

MGC’s botanic division’s collaboration with the University of Ljubljana is also progressing on schedule in Slovenia.

Following the planting of medicinal cannabis seeds for a genetic research program in June 2017, the plants have now progressed to the flowering phase.

The program aims to create genetic strains with high levels of CBD and new strains with high tetrahydrocannabinol (THC) levels for the treatment of specific disease symptoms.

The team will now commence a research project which will focus on the implementation and optimisation of molecular markers for sex determination and distinction between strains.

MGC’s raw material production at its open field farm in Slovenia has also delivered encouraging production volumes.

As planned, the company has completed harvesting of its cannabis crops, yielding 4,000 kilograms of biomass in early October 2017.





Register here to be notified of future MXC Company articles
View full MXC profile View Profile

MGC Pharmaceuticals Timeline

Related Articles

Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
Woman with tissue facing pollen
Fri
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
shutterstock_244380844.jpg
April 21 2017
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use